Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia

A Multi-center, Open-label, Observational Study to Evaluate the Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia

A Multi-center, Open-label, Observational Study to evaluate the Efficacy and Safety of Pitavastatin/Ezetimibe after switching from Statin Monotherapy to Pitavastatin/Ezetimibe in patients with Hypercholesterolemia

A Multi-center, Open-label, Observational Study

Inclusion Criteria:

• Adults (≥19 years) with hypercholesterolemia.
• On a stable dose of statin monotherapy for at least 8 weeks.
• Scheduled to switch to Pitavastatin/Ezetimibe per investigator's decision.
• Provided voluntary written informed consent.

Exclusion Criteria:

• Use of other lipid-lowering therapies within 4 weeks before screening.
• History of clinically significant laboratory abnormalities within 1 year.
• Participation in other clinical trials within 4 weeks.
• Contraindications to Pitavastatin/Ezetimibe